147 related articles for article (PubMed ID: 31479550)
1. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications.
Wu R; Chen H; Chang N; Xu Y; Jiao J; Zhang H
Chemistry; 2020 Jan; 26(6):1166-1195. PubMed ID: 31479550
[TBL] [Abstract][Full Text] [Related]
2. Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV.
Wender PA; Hardman CT; Ho S; Jeffreys MS; Maclaren JK; Quiroz RV; Ryckbosch SM; Shimizu AJ; Sloane JL; Stevens MC
Science; 2017 Oct; 358(6360):218-223. PubMed ID: 29026042
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
Raghuvanshi R; Bharate SB
Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
[TBL] [Abstract][Full Text] [Related]
4. New approaches to the total synthesis of the bryostatin antitumor macrolides.
Hale KJ; Manaviazar S
Chem Asian J; 2010 Apr; 5(4):704-54. PubMed ID: 20354984
[TBL] [Abstract][Full Text] [Related]
5. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.
DeChristopher BA; Loy BA; Marsden MD; Schrier AJ; Zack JA; Wender PA
Nat Chem; 2012 Sep; 4(9):705-10. PubMed ID: 22914190
[TBL] [Abstract][Full Text] [Related]
6. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.
Sloane JL; Benner NL; Keenan KN; Zang X; Soliman MSA; Wu X; Dimapasoc M; Chun TW; Marsden MD; Zack JA; Wender PA
Proc Natl Acad Sci U S A; 2020 May; 117(20):10688-10698. PubMed ID: 32371485
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core.
Kraft MB; Poudel YB; Kedei N; Lewin NE; Peach ML; Blumberg PM; Keck GE
J Am Chem Soc; 2014 Sep; 136(38):13202-8. PubMed ID: 25207434
[TBL] [Abstract][Full Text] [Related]
8. Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity.
Keck GE; Poudel YB; Rudra A; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Bioorg Med Chem Lett; 2012 Jun; 22(12):4084-8. PubMed ID: 22579485
[TBL] [Abstract][Full Text] [Related]
9. Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.
Keck GE; Poudel YB; Welch DS; Kraft MB; Truong AP; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Org Lett; 2009 Feb; 11(3):593-6. PubMed ID: 19113896
[TBL] [Abstract][Full Text] [Related]
10. The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.
Wender PA; Verma VA
Org Lett; 2008 Aug; 10(15):3331-4. PubMed ID: 18588309
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.
Irie K; Yanagita RC
Chem Rec; 2014 Apr; 14(2):251-67. PubMed ID: 24677503
[TBL] [Abstract][Full Text] [Related]
12. Marine natural products: bryostatins in preclinical and clinical studies.
Kollár P; Rajchard J; Balounová Z; Pazourek J
Pharm Biol; 2014 Feb; 52(2):237-42. PubMed ID: 24033119
[TBL] [Abstract][Full Text] [Related]
13. Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.
Wender PA; Nakagawa Y; Near KE; Staveness D
Org Lett; 2014 Oct; 16(19):5136-9. PubMed ID: 25238583
[TBL] [Abstract][Full Text] [Related]
14. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
Ruan BF; Zhu HL
Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
[TBL] [Abstract][Full Text] [Related]
15. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
Kedei N; Lewin NE; Géczy T; Selezneva J; Braun DC; Chen J; Herrmann MA; Heldman MR; Lim L; Mannan P; Garfield SH; Poudel YB; Cummins TJ; Rudra A; Blumberg PM; Keck GE
ACS Chem Biol; 2013 Apr; 8(4):767-77. PubMed ID: 23369356
[TBL] [Abstract][Full Text] [Related]
16. Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.
Wender PA; Staveness D
Org Lett; 2014 Oct; 16(19):5140-3. PubMed ID: 25238640
[TBL] [Abstract][Full Text] [Related]
17. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
[TBL] [Abstract][Full Text] [Related]
19. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.
Wender PA; Hinkle KW; Koehler MF; Lippa B
Med Res Rev; 1999 Sep; 19(5):388-407. PubMed ID: 10502742
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum: Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications.
Wu R; Chen H; Chang N; Xu Y; Jiao J; Zhang H
Chemistry; 2020 Jun; 26(32):7330. PubMed ID: 32500949
[No Abstract] [Full Text] [Related]
[Next] [New Search]
